About: Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma (en) Study of Mapatumumab in Combination With Bortezomib (nl)
skos:prefLabel	Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma (en) Study of Mapatumumab in Combination With Bortezomib (nl)
name	Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma (en) Study of Mapatumumab in Combination With Bortezomib (nl)
title	wds:Q65391095-13FF0D6D-08DA-4DFC-9085-17F83926CBD0
title	A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma (en)
end time	wds:Q65391095-349B5125-3FBD-4DC8-BA04-33CDA8BE07C4
end time	2010-10-01 00:00:00Z (xsd:dateTime)
instance of	wds:Q65391095-89ED817E-1B4B-4D39-9041-CFF81042F008
instance of	clinical trial
start time	wds:Q65391095-B40A1562-FE1E-4195-A224-F748237638B4
start time	2006-05-01 00:00:00Z (xsd:dateTime)
country	wds:Q65391095-503D8E13-5D86-47D6-A567-E9CF3F3C827F wds:Q65391095-6DF65D98-7A9E-498C-9B87-FED62692CB55 wds:Q65391095-76FDB1F2-AF18-4E55-AD8E-1088182EF0C6 wds:Q65391095-B5AC10B9-6C7F-4709-8A52-A5267DE2A68D
country	India Malawi Australia United States of America
research site	wds:Q65391095-39DFA3D5-0AF4-48EE-AEE3-824FFB6C5D97 wds:Q65391095-44C55C50-72AB-4BE1-9728-4A2A9B26425A wds:Q65391095-5DDEAFE9-7B50-4C50-9DEF-9F15E9B2892B wds:Q65391095-E45CFE8E-4391-4FF0-8E56-42F3E189035E
research site	All India Institute of Medical Sciences, Patna Cross Cancer Institute University of Chicago Roswell Park Comprehensive Cancer Center
minimum age	wds:Q65391095-38D19CD3-1E26-4666-8BD9-15E6C3609B8F
minimum age	18 (xsd:decimal)
medical condition	wds:Q65391095-E481538E-787F-4D18-A0A9-3E5C087F5069
medical condition	multiple myeloma
number of participants	wds:Q65391095-8431E820-A4EE-4DB3-8CB4-8CEC396DF6CC
number of participants	105 (xsd:decimal)
study type	wds:Q65391095-8BE008BD-695C-41D6-A684-8C5DA3444E26
study type	interventional study
ClinicalTrials.gov ID	wds:Q65391095-923E68E0-064E-4710-AC4E-AA74B3DF6F89
ClinicalTrials.gov ID	NCT00315757
clinical trial phase	wds:Q65391095-216E495C-AB46-473B-BC37-A9FBFCBE73EF
clinical trial phase	phase II clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q65391095

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software